Use of Mepolizumab in Children and Adolescents with Asthma in the USA

Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe have significantly higher healthcare costs compared to those non-severe disease. Biologics are newest class anti-asthma therapy approved for use in patients > 6 years eosinophilic phenotype. Objective: The goals this study were (1) describe baseline characteristics new mepolizumab users between 2015 end dates that varied by data partner (6/30/19–5/31/21), (2) medication 12 months preceding following initiation group (3) assess adherence persistence initiation. Methods: Through an observational cohort using insurance claim databases, we studied a diagnosis who started had follow-up data. Results: Baseline 72 initiated showed variable comorbidities, most common being allergic rhinitis (88%) recurrent respiratory infections (71%), as well dispensings patterns utilization prior initiating mepolizumab. Half met criteria per GINA guidelines. Comparing weighted averages treatments dispensed versus initiation, observed no significant change dispensed. Conclusion: This demonstrates prescribed previous treatment history severity disease, found evidence alters other medications first